Mission Statement, Vision, & Core Values (2026) of Kangji Medical Holdings Limited.

Founded in 2004 and headquartered in Hangzhou, Kangji Medical Holdings Limited (listed on the mainboard of the Hong Kong Stock Exchange since June 2020 under 9997.HK) combines a clear mission-to provide physicians with high-quality products and services to improve people's health-with a bold vision to become the world's leading medical device enterprise; the company supplies tailored minimally invasive solutions across obstetrics and gynecology, general surgery, urology and thoracic surgery, has reached over 3,500 hospitals including more than 1,000 Class IIIA hospitals, expanded into over 80 countries and regions, and backs its global ambition with robust R&D (allocating about 10% of annual revenue) and a patent portfolio exceeding 270 registered patents, all guided by core values-Customers First, Embrace Innovation, Demonstrate Integrity and Be Proactive-that drive product excellence, customer support and strategic initiatives such as recent moves toward privatization to accelerate long-term growth

Kangji Medical Holdings Limited (9997.HK) Intro

• Founded: 2004 (Hangzhou, Zhejiang, China)
• Hong Kong Main Board listing: June 2020 (Stock code: 9997.HK)
• Core specialties: Obstetrics & gynecology, general surgery, urology, thoracic surgery
• Global footprint: Presence in over 80 countries and regions (as of late 2025)
• Hospital coverage: Products used in over 3,500 hospitals, including >1,000 Class IIIA hospitals (as of late 2025)
• Intellectual property: Over 270 registered patents

• Mission: To develop and deliver safe, effective, and accessible minimally invasive surgical instruments and tailored solutions that improve surgical outcomes worldwide.
• Vision: To be an internationally recognized platform for minimally invasive surgical instruments and accessories with comprehensive global coverage and clinical leadership.
• Core values: Patient safety, clinical collaboration, innovation, quality, integrity, and global responsibility.

• R&D intensity: Sustained investment in product development and clinical validation; over 270 patents registered across key device categories.
• Product portfolio: Comprehensive offerings spanning disposable and reusable devices, instrument systems, and accessories to support full-procedure workflows.
• Clinical network: Broad adoption within tertiary hospitals (including >1,000 Class IIIA hospitals) and strong ties with surgical key opinion leaders.

• Public listing provides enhanced capital access to fund R&D, capacity expansion, and international commercialization.
• Investors seeking detailed financial performance and trend analysis can refer to the company-focused financial review: Breaking Down Kangji Medical Holdings Limited Financial Health: Key Insights for Investors

Kangji Medical Holdings Limited (9997.HK) - Overview

• Kangji Medical's mission is to provide physicians with high-quality products and services, dedicating itself to improving people's health.
• Commitment to enhancing healthcare outcomes by delivering reliable and effective medical devices and consumables to hospitals, clinics and distributors.
• Focus on both product excellence and comprehensive customer support - sales, training, technical after-sales and logistics.
• Patient-centric approach: product selection, partnerships and service models are intended to improve clinical outcomes and patient safety.
• Strategic orientation: mission has driven expansion of product portfolios, geographic reach and vertical capabilities (distribution, OEM, service).
• Corporate action alignment: recent corporate moves, including the proposed privatization, are positioned as steps to accelerate long-term innovation and sustainable growth consistent with the mission.

• To be a leading regional medical device platform that empowers clinicians with advanced, safe and accessible technologies.
• To scale a trusted ecosystem that bridges international suppliers with local healthcare providers, improving care delivery across Greater China and selected APAC markets.
• To integrate product innovation, data-driven service and supply-chain excellence to raise the standard of care.

• Quality: adherence to regulatory standards and continuous quality improvement across sourcing, distribution and service.
• Integrity: transparent partnerships, ethical commercialization and patient-first decision-making.
• Collaboration: long-term supplier and clinical partnerships to deliver tailored solutions.
• Innovation: investing in new product introduction, clinical training and selective R&D to meet evolving clinical needs.
• Accountability: measurable performance targets for safety, delivery times and customer satisfaction.

• Product portfolio expansion - number of SKUs and new supplier relationships increased year-over-year to broaden clinical coverage and revenue diversification.
• Clinical support metrics - in-market training sessions, CE/ISO-aligned quality checks and service level agreements elevated customer retention.
• Capital allocation - a portion of operating cashflow prioritized for selective M&A, inventory support and clinical commercialization to accelerate adoption.
• Corporate governance moves - the proposed privatization reflects a strategic choice to enable longer-term investments off the public market timetable and better align with the mission-driven growth plan.

• Investors evaluate Kangji Medical on revenue growth, margin sustainability, product mix and the ability to scale clinical distribution with quality controls in place.
• Customers and clinicians monitor product availability, training support and post-sale service metrics tied to patient outcomes.
• Employees and partners consider the company's commitment to quality, compliance and innovation when engaging in long-term collaborations.

Kangji Medical Holdings Limited (9997.HK) - Mission Statement

• Global leadership: establish product and technology standards across therapeutic areas served by Kangji Medical.
• Innovation-driven growth: allocate roughly 10% of annual revenue to R&D to accelerate device development and regulatory approvals.
• Quality & compliance: achieve and maintain international certifications and regulatory clearances (CE, NMPA, FDA pathways where applicable).
• Accessible healthcare: expand distribution and training to reach hospitals and clinics across emerging and developed markets.

Kangji Medical's vision is to be the world's leading medical device enterprise. That ambition drives strategic priorities: product platform development, scalable manufacturing, regulatory footprint expansion and partnerships with global distributors and clinical institutions. The vision has remained consistent and continues to guide capital allocation, M&A consideration and operational metrics.

• Geographic reach: presence in over 80 countries and regions through direct operations, distributors and licensing partners.
• R&D commitment: approximately 10% of annual revenue invested in innovation, signaling a sustained pipeline emphasis.
• Standards leadership: target to set clinical and manufacturing benchmarks within core product categories over the next 5-10 years.

• Capital allocation priorities: sustain ~10% R&D while targeting operating leverage through manufacturing scale and selective geographic expansion.
• Performance metrics tied to vision: CAGR in revenue, number of regulatory clearances per year, international market penetration and product portfolio diversification.

Kangji Medical Holdings Limited (9997.HK): Vision Statement

• Deliver high-quality, cost-effective medical technologies that address unmet clinical needs.
• Partner with healthcare providers to improve patient outcomes and operational efficiency.
• Invest strategically in R&D and commercialization to convert scientific advances into scalable clinical solutions.

• Customers First - Prioritize clinician and patient needs in product design, service delivery, and post-market support to ensure high satisfaction and safety.
• Embrace Innovation - Commit resources to continuous improvement, platform R&D, and cross-disciplinary collaboration to maintain technological leadership.
• Demonstrate Integrity - Uphold ethical conduct, transparent governance, and regulatory compliance across manufacturing, distribution, and clinical claims.
• Be Proactive - Anticipate regulatory shifts, clinical trends, and market dynamics to accelerate time-to-market and mitigate operational risks.

• Revenue Growth Targets - sustainable mid-to-high single-digit organic growth, supplemented by strategic M&A to accelerate capability gaps.
• Margin Management - focus on gross margin expansion via higher-margin product mix and operational efficiencies; target adjusted gross margin improvement of 200-400 basis points over a 3-year horizon.
• R&D Efficiency - measure new product revenue as percentage of total revenue; aim for 20-30% of annual revenue to come from products launched within the last 3 years.

• Board oversight aligns incentives with long-term value creation; compliance KPIs integrated into executive scorecards.
• Robust pharmacovigilance and quality management systems to reduce product recall risk and ensure patient safety.
• Transparent investor communication and IR cadence to maintain market confidence; see investor profile for further context: Exploring Kangji Medical Holdings Limited Investor Profile: Who's Buying and Why?

• Embed core values into performance reviews, hiring, and internal training curricula.
• Target employee retention and development metrics: annual turnover ≤12% in R&D/clinical teams; internal promotion rate ≥25% for mid-level roles.
• Support cross-functional teams to accelerate commercialization cycles from prototype to launch (target cycle: 24-36 months for priority projects).